MVTs: Novel Metronidazole-Berberine Conjugates for Antibacterial Research

340.2 KB of structural data for novel metronidazolyl vinylthiazolidionyl tetrahydroberberine (MVT) compounds. The dataset, authored by Yu Zhou and last updated in 2026, includes results from medicinal chemobiological investigations showing that compound 7b was 69-fold more active than berberine against S. aureus 25923. The work demonstrates the compounds' multitargeting antibacterial potential to address bacterial resistance.

Use Cases

• Predicting antibacterial activity based on novel MVT structural skeletons described in the research.
• Modeling drug-likeness based on described properties like low hemolysis, cytotoxicity, and efficient transport by human serum albumin.
• Analyzing structure-activity relationships for compounds designed to disrupt bacterial membranes, trigger oxidative stress, and intercalate into DNA.

Strengths

• Specific MIC value (0.005 mM) reported for the most active compound, 7b, against S. aureus 25923.
• Comparative potency data provided, showing 7b was 3-fold more active than norfloxacin and 69-fold more active than berberine.
• Multiple biological endpoints described, including hemolysis, cytotoxicity, drug resistance, biofilm eradication, and in vivo potency.

Limitations

• Row count is unknown, which may limit suitability assessment for large-scale modeling.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect experimental bias inherent to the specific in vitro and in vivo assays described.

Provenance

Source

figshare

Collection Method

Experimental synthesis and biological evaluation of novel chemical conjugates.

Freshness

Last updated 2026-05-26 08:05:52; freshness should be verified.